Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Idecabtagene vicleucel (ide-cel) is the first FDA-approved CAR T-cell therapy for multiple myeloma.
• Clinical trials often have strict eligibility criteria, limiting real-world applicability.

Purpose of the Study:

• To assess the safety and effectiveness of standard of care (SOC) ide-cel in a real-world multiple myeloma patient population.
• To compare real-world outcomes with findings from clinical trials.

Main Methods:

• Retrospective analysis of 821 patients receiving SOC ide-cel from the CIBMTR registry.
• Evaluation of patient demographics, comorbidities, prior therapies, and treatment outcomes.

Main Results:

• Overall response rate (ORR) was 73% with a 25% complete response (CR) rate.
• Median progression-free survival (PFS) was 8.8 months; treatment-related mortality was 6%.
• High rates of cytokine release syndrome (80%) and neurotoxicity (28%) were observed, mostly low-grade.

Conclusions:

• SOC ide-cel demonstrates a favorable safety and efficacy profile in real-world multiple myeloma patients.
• Outcomes mirror clinical trial data, even in patients with significant comorbidities often excluded from trials.